The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
May 3rd 2025
Reductions of about 32% were observed during the study.
Nivolumab Receives FDA Approval as an Adjuvant Melanoma Treatment
December 22nd 2017The FDA recently approved nivolumab (Opdivo) for the treatment of patients with melanoma whose disease has spread to the lymph nodes or those with metastatic disease who have undergone resection, according to a press release.
Read More
FDA Grants Accelerated Approval to Chronic Myelogenous Leukemia Drug
December 22nd 2017Officials with the FDA granted accelerated approval to bosutinib (Bosulif) for the treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).
Read More
FDA OKs Drug for Critically Low Blood Pressure in Septic Shock
December 22nd 2017Officials with the FDA have approved angiotensin II (Giapreza, La Jolla Pharmaceutical Company) injection for intravenous infusion to treat dangerously low blood pressure in adults with septic or other distributive shock.
Read More
FDA Approves HER2+ Breast Cancer Therapy
December 21st 2017Officials with the FDA have approved pertuzumab (Perjeta, Roche) in combination with trastuzumab and chemotherapy as an adjuvant therapy for patients with early-stage human epidermal growth factor receptor 2 positive (HER2+) breast cancer who are at high risk of experiencing recurrence.
Read More
Flu Vaccine Practice Guideline: Egg-Based Vaccines Safe for Those with Egg Allergy
December 21st 2017Health care providers can administer egg-based influenza vaccines to people with egg allergy without taking precautions, according to a newly-updated influenza vaccine practice parameter from the Influenza Vaccine and Egg Allergy Practice Parameter Workgroup commissioned by Joint Task Force on Practice Parameters (JTFPP).
Read More
FDA OKs Gene Therapy for Rare Mutation-Associated Vision Loss
December 19th 2017Officials with the FDA have approved voretigene neparvovec-rzyl (Luxturna, Spark Therapeutics), the first novel gene therapy for the treatment of an inherited form of vision loss in children and adults, according to an FDA press release.
Read More
FDA Officials Warn About MRI Dye
December 19th 2017FDA officials are now requiring a new patient medication guide, providing educational information that every patient will be asked to read before receiving a GBCA, and they are requiring manufacturers of GBCAs to conduct human and animal studies to further assess the safety of these contrast agents.
Read More